A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
NOVARTIS PROVIDES CANDIDATE DRUG
COMPOUNDS TO THE GLOBAL ALLIANCE
FOR TB DRUG DEVELOPMENT
Novartis has signed a licensing agreement with the Global Alliance for TB Drug Development for compounds discovered at Novartis Institutes for Tropical Diseases (NITD). Under this agreement, NITD will transfer its TB R&D program to the TB Alliance, including research, development, approval and distribution responsibilities. Read more on the Novartis website here.
Recent News and Announcements
RESIST-TB has been awarded support from the Firland Foundation for a project proposal entitled “Monitoring Compassionate Use of New TB Drugs for MDR-TB and XDR-TB.” The project aims to survey high-burden countries and assess the demand for compassionate use in these areas, identify barriers to access, publicize these barriers, and propose potential ways to increase […]
Johnson & Johnson’s affiliate Janssen Pharmaceutica NV (Janssen) has entered into a collaboration with Stichting International Dispensary Association (IDA) which is a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF) to facilitate access to the Company’s anti-tuberculosis medicine. More than 130 low- and middle-income countries outside of the United States will now […]
Treatment Action Campaign (TAC) has called upon the South African government to declare tuberculosis a public health emergency. Activists with TAC released a statement at the 4th South Africa TB Conference in Durban on June 10th demanding a halt to drug-resistant tuberculosis. In South Africa, tuberculosis kills at least 148 people and infects approximately 1,400 people […]
Otsuka pharmaceuticals has announced a framework for reviewing requests for compassionate use of delamanid. The drug, which has recently gained European marketing authorization, has been provided to only three patients under compassionate use thus far, including a pediatric extensively drug-resistant tuberculosis patient (detailed here). The announcement comes after advocates have pushed the company to establish a […]
Otsuka pharmaceuticals announced on April 30th that the European commission has approved marketing authorization for delamanid (Deltyba) for treatment of pulmonary multidrug-resistant tuberculosis. The drug has been approved for use in adults when an effective treatment regimen is not available due to resistance or intolerance. Delamanid is still under approval in Japan. See the full Otsuka […]